[go: up one dir, main page]

MX2024012290A - Compuestos derivados de 1,3,4-oxadiazol como inhibidor de la histona desacetilasa 6, y usos de los mismos - Google Patents

Compuestos derivados de 1,3,4-oxadiazol como inhibidor de la histona desacetilasa 6, y usos de los mismos

Info

Publication number
MX2024012290A
MX2024012290A MX2024012290A MX2024012290A MX2024012290A MX 2024012290 A MX2024012290 A MX 2024012290A MX 2024012290 A MX2024012290 A MX 2024012290A MX 2024012290 A MX2024012290 A MX 2024012290A MX 2024012290 A MX2024012290 A MX 2024012290A
Authority
MX
Mexico
Prior art keywords
histone deacetylase
diseases
inhibitor
hdac6
derivative compounds
Prior art date
Application number
MX2024012290A
Other languages
English (en)
Inventor
Chang Sik Lee
Jung Taek Oh
Hyeseung Song
Hyunjin Michael Kim
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of MX2024012290A publication Critical patent/MX2024012290A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a un compuesto novedoso que tiene actividad inhibidora de la histona desacetilasa 6 (HDAC6), a un método para preparar el mismo y a usos del mismo. El compuesto novedoso de acuerdo con la presente invención, un estereoisómero del mismo o una sal farmacéuticamente aceptable del mismo tiene actividad inhibidora de HDAC6, y es eficaz para prevenir o tratar enfermedades mediadas por la HDAC6, incluyendo el cáncer, enfermedades inflamatorias, enfermedades autoinmunitarias, enfermedades neurológicas o neurodegenerativas.
MX2024012290A 2022-04-07 2024-10-03 Compuestos derivados de 1,3,4-oxadiazol como inhibidor de la histona desacetilasa 6, y usos de los mismos MX2024012290A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020220043429A KR102904231B1 (ko) 2022-04-07 2022-04-07 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도
PCT/KR2023/004684 WO2023195809A1 (en) 2022-04-07 2023-04-06 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and uses thereof

Publications (1)

Publication Number Publication Date
MX2024012290A true MX2024012290A (es) 2024-11-08

Family

ID=88243276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012290A MX2024012290A (es) 2022-04-07 2024-10-03 Compuestos derivados de 1,3,4-oxadiazol como inhibidor de la histona desacetilasa 6, y usos de los mismos

Country Status (9)

Country Link
US (1) US20260028321A1 (es)
EP (1) EP4504713A1 (es)
JP (1) JP2025512815A (es)
KR (1) KR102904231B1 (es)
CN (1) CN119233968A (es)
CA (1) CA3254864A1 (es)
MX (1) MX2024012290A (es)
TW (1) TW202345812A (es)
WO (1) WO2023195809A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105727298A (zh) 2010-01-22 2016-07-06 埃斯泰隆制药公司 作为蛋白质去乙酰化酶抑制剂的反向酰胺化合物及其使用方法
WO2013134467A1 (en) 2012-03-07 2013-09-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
US10538498B2 (en) * 2015-07-27 2020-01-21 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
HUE051537T2 (hu) * 2015-07-27 2021-03-01 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolamid-származék vegyület mint hiszton deacetiláz 6 inhibitor és ezt tartalmazó gyógyszerkészítmény
CA2994688C (en) * 2015-08-04 2020-11-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2020158762A1 (ja) * 2019-01-30 2020-08-06 武田薬品工業株式会社 複素環化合物
EP3990618A4 (en) * 2019-06-27 2023-08-09 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS AND ASSOCIATED USES

Also Published As

Publication number Publication date
EP4504713A1 (en) 2025-02-12
KR102904231B1 (ko) 2025-12-29
KR20230144686A (ko) 2023-10-17
TW202345812A (zh) 2023-12-01
CN119233968A (zh) 2024-12-31
US20260028321A1 (en) 2026-01-29
CA3254864A1 (en) 2023-10-12
AU2023248256A1 (en) 2024-09-19
WO2023195809A1 (en) 2023-10-12
JP2025512815A (ja) 2025-04-22

Similar Documents

Publication Publication Date Title
MX2022000271A (es) Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos.
MX2023001689A (es) Inhibidores de bcl-2.
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
SA522433000B1 (ar) مركبات فلورو ألكيل-أوكساديازول واستخداماتها
CL2023003308A1 (es) Compuestos heterocíclicos sustituidos
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
AR128931A1 (es) Inhibidores del factor b del complemento y usos de los mismos
CL2022003360A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578)
MX2021011606A (es) Compuestos dirigidos a prmt5.
AR127645A1 (es) Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
MX2022010402A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
MX2024008886A (es) Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2.
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
MX2024012290A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidor de la histona desacetilasa 6, y usos de los mismos
MX2023013351A (es) Compuestos heterociclicos sustituidos.
CL2025000529A1 (es) Compuestos derivados de dioxoisoquinolinona, inhibidores de ezh1 y/o ezh2; uso para tratar cáncer.
MX2022010394A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
MX2022012844A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
CO2024012770A2 (es) Inhibidores de proteínas de unión a emopamilo y usos de estos
MX2025002435A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y usos de los mismos
AR129959A1 (es) Método para tratar enfermedades o trastornos orgánicos con inhibidores de ask1